Belén Garijo is the Chair of the Executive Board and CEO of Merck. She joined Merck in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. Before taking her current office in May 2021, Belén Garijo served as Vice-Chair of the Executive Board and Deputy CEO.
Before joining Merck, Belén Garijo served as the Senior Vice President Global Operations Europe at Sanofi-Aventis, where she was also a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003, she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer.
Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA.
Public confidence in science and trust in scientists has rarely been higher than it is today. Worldwide, most people believe science is the best path toward a better, healthier, and more ...
Over the last two decades, data and digital technologies have begun to converge with medicines, devices, and diagnostics to create a new market for digital health. The Covid-19 pandemic h...
Neglected tropical diseases (NTDs) affect the lives of more than 1 billion people worldwide and represent an often-overlooked global health burden that translates into lost opportunities ...
Cancer is pervasive and does not discriminate. It was responsible for 18.1 million new cases and 9.6 million deaths worldwide in 2018, and these numbers are expected to nearly double by 2...
新型コロナウイルスの大流行により介護の必要性が増し、予期せぬ大きな課題が提起される中、介護者を認識し、評価し、性差による偏向を減らしていくことの緊急性が高まっています。特に、リソースが限られ、患者の多くが入院できない状況において、新型コロナウイルスの患者とその家族にとって、緩和ケアおよび終末期ケアは必要性の高いものになると考えられます。
The COVID-19 pandemic increases the urgency of recognizing and valuing carers and reducing gender bias because it presents enormous and unexpected challenges associated with increased car...
“Change is the only constant.” These words of wisdom from the ancient Greek philosopher Heraclitus still hold true today. It is most certainly true of the pharmaceutical sector where chan...
It will take 108 years to close the overall global gender gap, according to the World Economic Forum’s 2018 Gender Gap Report. One doesn’t have to look far to see the real-world inequalit...
A new understanding of disease biology is emerging. In a paradigm shift towards what is known as molecular pathology, medical science is increasingly looking at diseases at a molecular le...
